Heart disease risk among metabolically healthy obese men and metabolically unhealthy lean men

In this issue of CMAJ, St-Pierre and colleagues1 present the results of a longitudinal cohort study conducted in Quebec to determine the contribution of metabolic factors to cardiovascular disease. The authors found that among study participants, the risk of ischemic heart disease increased when components of insulin resistance syndrome, or the metabolic syndrome (MetS), were present. Specifically, they determined that although obese men were more likely to have the MetS, obese men without the MetS were not at increased risk of ischemic heart disease. Conversely, lean men with the MetS had an increased risk of ischemic heart disease.

The MetS represents a clustering of cardiovascular disease and diabetes risk factors that include high blood pressure, dyslipidemia and high blood glucose levels. The MetS has been given many names, including insulin resistance syndrome,2 syndrome X3 and the deadly quartet.4 Only recently has a general consensus been reached to use the term “metabolic syndrome,” which has in part contributed to the development of an International Classification of Disease code (277.7) for this condition. Numerous risk factors and criteria have been used to diagnose the MetS (e.g., the criteria used by St-Pierre and colleagues1), and at present there are no globally accepted diagnosis criteria. The most commonly employed clinical criteria are based on the US National Cholesterol Education Program guidelines5 and include the presence of at least 3 of the following: high blood pressure (≥ 130/85 mm Hg), high triglyceride levels (≥ 1.60 mmol/L), low high-density lipoprotein cholesterol levels (< 1.04 mmol/L), high fasting glucose levels (≥ 6.1 mmol/L) and central obesity (waist circumference > 102 cm in men and > 88 cm in women). Using these criteria, about 17% of Canadian men and 13% of Canadian women have the MetS.6

The MetS is a strong risk factor for type 2 diabetes (hazard ratio [HR] 3.51, 95% confidence interval [CI] 2.47–4.98),7 coronary artery disease (HR 2.96, 95% CI 2.36–3.79)8 and premature mortality (HR 1.81, 95% 1.24–2.65).8 There are multiplicative effects between the components of the MetS and disease risk, such that the MetS predicts disease outcomes to a greater extent than the sum of the risk estimates of the individual MetS components.9 This speaks to the clinical importance of identifying high-risk patients with the MetS.

Obesity is one of the central components in the development of the MetS. The likelihood of having the MetS is increased by more than 5-fold in overweight people and by more than 20-fold in obese people in comparison with people with a healthy body weight.10 Thus, from a population perspective, preventing and treating obesity would help reduce the incidence of the MetS. In both the clinical and research setting, adiposity status is typically classified according to the body mass index (BMI), which is determined by taking a person's weight and dividing it by the square of their height (kg/m²). Among adults, BMI values of 25–29.9 kg/m² indicate overweight, and BMI values of 30 kg/m² or more indicate obesity.11 Although there are more direct and accurate methods for classifying adiposity status than BMI, such as underwater weighing measures of body fat, these body composition measures are impractical for the clinical setting.

Despite the strong relation between adiposity level and the MetS, about 40% of the obese population does not have the MetS,10 a condition that has been termed “metabolically normal, obese.” Conversely, about 6% of the normal-weight population has the MetS,10 a condition that has been termed “metabolically obese, normal weight.” In their study, St-Pierre and colleagues1 determined that the risk of ischemic heart disease is increased among “metabolically obese, normal weight” people but not among “metabolically normal, obese” people.

These findings raise the question as to whether health care practitioners should prescribe weight loss to obese patients who do not have the MetS. The answer to this question is a resounding “yes.” In addition to the MetS, obesity is a risk factor for numerous other health outcomes (e.g., arthritis, certain cancers, depression),11 and weight loss in obese people without the MetS will offer protection against these nonmetabolic diseases. Further, because the duration of overweight and obesity is associated with the presence of the MetS,12 weight loss in obese people without the MetS may offer some protection against the development of this condition.

The findings of St-Pierre and colleagues1 also raise the question as to what treatments should be prescribed for normal-weight patients with the MetS. Pharmacologic treatment of the individual components of the MetS will be the preferred approach of many clinicians and patients.13 Lifestyle changes should, however, be given an equal if not greater emphasis. Expert committees recommend that normal-weight patients (as well as overweight and obese patients) with the MetS should improve their physical activity and dietary habits.5^,14 A recent study found that 31% of patients with the MetS were no longer classified as having the syndrome after participating in a 20-week aerobic exercise program.15 Furthermore, a high physical fitness level greatly attenuates the increased cardiovascular disease risk among normal-weight (as well as overweight and obese) people with the MetS.16 Regarding diet, there is great debate as to the optimal proportions of carbohydrates, protein and fat to treat the MetS.17 Physicians and dieticians may therefore want to focus on each patient's specific metabolic alterations,18 such as reducing salt intake in patients with high blood pressure.

In summary, the MetS is a highly prevalent condition that is associated with an increased morbidity and mortality risk. Obesity is a risk factor for the MetS; however, patients with the MetS have an increased risk of ischemic heart disease regardless of their adiposity status. The MetS in all patients should be aggressively treated.

𝛃 See related article page 1301